Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics

Diabetes mellitus is a major health problem with increasing prevalence at a global level. The discovery of insulin in the early 1900s represented a major breakthrough in diabetes management, with further milestones being subsequently achieved with the identification of glucagon-like peptide-1 (GLP-1...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmaceutica Sinica. B 2022-02, Vol.12 (2), p.621-636
Main Authors: Bendicho-Lavilla, Carlos, Seoane-Viaño, Iria, Otero-Espinar, Francisco J., Luzardo-Álvarez, Asteria
Format: Article
Language:English
Subjects:
Amylin mimetics
Biotherapeutics
Controlled-release formulations
Drug delivery systems
Exenatide
Glucagon-like peptide-1 receptor agonists
Microparticles
Nanoparticles
Peptide delivery
Review
Subcutaneous administration
Type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes mellitus is a major health problem with increasing prevalence at a global level. The discovery of insulin in the early 1900s represented a major breakthrough in diabetes management, with further milestones being subsequently achieved with the identification of glucagon-like peptide-1 (GLP-1) and the introduction of GLP-1 receptor agonists (GLP-1 RAs) in clinical practice. Moreover, the subcutaneous delivery of biotherapeutics is a well-established route of administration generally preferred over the intravenous route due to better patient compliance and prolonged drug absorption. However, current subcutaneous formulations of GLP-1 RAs present pharmacokinetic problems that lead to adverse reactions and treatment discontinuation. In this review, we discuss the current challenges of subcutaneous administration of peptide-based therapeutics and provide an overview of the formulations available for the different routes of administration with improved bioavailability and reduced frequency of administration. This review summarises the current challenges of subcutaneous administration of peptide-based antidiabetics and provides an overview of the formulations available for the different routes of administration. [Display omitted]
ISSN:2211-3835
2211-3843
DOI:10.1016/j.apsb.2021.08.003